<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="70712"><DrugName>vamorolone</DrugName><DrugNamesKey><Name id="42981302">vamorolone</Name></DrugNamesKey><DrugSynonyms><Name><Value>non-hormonal steroid (asthma), Validus Biopharma</Value></Name><Name><Value>vamorolone</Value><Types><Type>INN</Type></Types></Name><Name><Value>verolone</Value></Name><Name><Value>VB-15</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VBP-15</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>13209-41-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1060605">ReveraGen BioPharma Inc</CompanyOriginator><CompaniesPrimary><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Company id="1060605">ReveraGen BioPharma Inc</Company><Company id="1149835">Idorsia Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="23780">Actelion Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="70712" type="Drug"><TargetEntity id="555841" type="siDrug">Vamorolone</TargetEntity></SourceEntity><SourceEntity id="1060605" type="Company"><TargetEntity id="5035527134" type="organizationId">ReveraGen BioPharma Inc</TargetEntity></SourceEntity><SourceEntity id="1149835" type="Company"><TargetEntity id="5056400072" type="organizationId">Idorsia Ltd</TargetEntity></SourceEntity><SourceEntity id="23780" type="Company"><TargetEntity id="4295890901" type="organizationId">Actelion Ltd</TargetEntity></SourceEntity><SourceEntity id="1532" type="ciIndication"><TargetEntity id="10047115" type="MEDDRA"/><TargetEntity id="D014657" type="MeSH"/><TargetEntity id="-865701041" type="omicsDisease"/><TargetEntity id="1201" type="siCondition"/></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="2020" type="ciIndication"><TargetEntity id="10013801" type="MEDDRA"/><TargetEntity id="D020388" type="MeSH"/><TargetEntity id="98896" type="ORPHANET"/><TargetEntity id="-2123687174" type="omicsDisease"/><TargetEntity id="143" type="siCondition"/></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity><SourceEntity id="2475" type="ciIndication"><TargetEntity id="M33" type="ICD10"/><TargetEntity id="10012503" type="MEDDRA"/><TargetEntity id="D003882" type="MeSH"/><TargetEntity id="221" type="ORPHANET"/><TargetEntity id="-990050583" type="omicsDisease"/><TargetEntity id="139" type="siCondition"/></SourceEntity><SourceEntity id="303" type="ciIndication"><TargetEntity id="10040641" type="MEDDRA"/><TargetEntity id="D000755" type="MeSH"/><TargetEntity id="232" type="ORPHANET"/><TargetEntity id="-2067923175" type="omicsDisease"/><TargetEntity id="994" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="3250" type="ciIndication"><TargetEntity id="D049288" type="MeSH"/><TargetEntity id="263" type="ORPHANET"/><TargetEntity id="-1070558393" type="omicsDisease"/><TargetEntity id="2684" type="siCondition"/></SourceEntity><SourceEntity id="3289" type="ciIndication"><TargetEntity id="10059117" type="MEDDRA"/><TargetEntity id="98895" type="ORPHANET"/><TargetEntity id="1905" type="siCondition"/></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"/><TargetEntity id="10011762" type="MEDDRA"/><TargetEntity id="D003550" type="MeSH"/><TargetEntity id="586" type="ORPHANET"/><TargetEntity id="-1447400656" type="omicsDisease"/><TargetEntity id="288" type="siCondition"/></SourceEntity><SourceEntity id="3191" type="Action"><TargetEntity id="1738" type="Mechanism">Glucocorticoid Receptor (GR) Agonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1089" type="Action"><TargetEntity id="2526" type="Mechanism">Mineralocorticoid Receptor (MR) Antagonists</TargetEntity></SourceEntity><SourceEntity id="2653" type="Action"><TargetEntity id="945" type="Mechanism">NF-kappaB (NFKB) Activation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01338" type="ciTarget"><TargetEntity id="13026020843063" type="siTarget">Mineralocorticoid receptor</TargetEntity><TargetEntity id="4362" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1532">Vasculitis</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="2020">Duchenne dystrophy</Indication><Indication id="213">Multiple sclerosis</Indication><Indication id="2475">Dermatomyositis</Indication><Indication id="303">Sickle cell anemia</Indication><Indication id="31">Asthma</Indication><Indication id="3250">Limb girdle muscular dystrophy</Indication><Indication id="3289">Becker muscular dystrophy</Indication><Indication id="88">Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action id="1089">Mineralocorticoid receptor antagonist</Action><Action id="3191">Glucocorticoid receptor agonist</Action><Action id="2653">Nuclear factor kappa B inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1408">Muscle system agent</Action><Action id="1470">Respiratory system agent</Action><Action id="2953">Anti-inflammatory</Action><Action id="2954">Steroidal anti-inflammatory</Action><Action id="56465">Mitosis stimulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><EphmraCodes><Ephmra><Code>R</Code><Name>RESPIRATORY SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-29T12:31:23.000Z</LastModificationDate><ChangeDateLast>2019-04-29T00:00:00.000Z</ChangeDateLast><AddedDate>2011-03-30T09:43:20.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1060605" linkType="Company"&gt;ReveraGen &lt;/ulink&gt;(formerly  Validus Biopharma), in collaboration with &lt;ulink linkID="1072251" linkType="Company"&gt;Therapeutics for Rare and Neglected Diseases&lt;/ulink&gt; (TRND) and &lt;ulink linkID="1149835" linkType="Company"&gt;Idorsia&lt;/ulink&gt; (a spin-off of &lt;ulink linkID="23780" linkType="Company"&gt;Actelion&lt;/ulink&gt;), is developing  the delta-9,11 glucocorticoid analog vamorolone (verolone, VBP-15 VB-15),  a lead from the &lt;ulink linkID="71002" linkType="Drug"&gt;VBP series&lt;/ulink&gt;,  for the potential oral treatment of Duchenne muscular dystrophy (DMD) [&lt;ulink linkID="1182509" linkType="Reference"&gt;1182509&lt;/ulink&gt;], [&lt;ulink linkID="1181884" linkType="Reference"&gt;1181884&lt;/ulink&gt;], [&lt;ulink linkID="1170957" linkType="Reference"&gt;1170957&lt;/ulink&gt;], [&lt;ulink linkID="1288502" linkType="Reference"&gt;1288502&lt;/ulink&gt;], [&lt;ulink linkID="1475238" linkType="Reference"&gt;1475238&lt;/ulink&gt;], [&lt;ulink linkID="1603478" linkType="Reference"&gt;1603478&lt;/ulink&gt;], [&lt;ulink linkID="1691990" linkType="Reference"&gt;1691990&lt;/ulink&gt;], [&lt;ulink linkID="1760091" linkType="Reference"&gt;1760091&lt;/ulink&gt;], [&lt;ulink linkID="1938314" linkType="Reference"&gt;1938314&lt;/ulink&gt;]. ReveraGen is also investigating the drug for the potential treatment of  Becker muscular dystrophy (BMD), cystic fibrosis, multiple sclerosis, sickle cell anemia , asthma and other inflammatory diseases including inflammatory bowel      disease (IBD) rheumatoid arthritis, ANCA-associated vasculitis (AAV) and Juvenile Dermatomyositis   and Calpain 3 Deficiency (LGMD2A), Limb Girdle Muscular Dystrophy Type 2B (LGMD2B)  [&lt;ulink linkID="1603478" linkType="Reference"&gt;1603478&lt;/ulink&gt;], [&lt;ulink linkID="2143834" linkType="Reference"&gt;2143834&lt;/ulink&gt;].  In June 2018, a phase IIb trial (VISION-DMD) was initiated in patients with DMD [&lt;ulink linkID="2066755" linkType="Reference"&gt;2066755&lt;/ulink&gt;]. In September 2015, a BMD clinical program was planned  [&lt;ulink linkID="1691990" linkType="Reference"&gt;1691990&lt;/ulink&gt;].  In November 2018, data filing for US and EU were expected by the end of 2020 and  2021, respectively [&lt;ulink linkID="2096928" linkType="Reference"&gt;2096928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2018, &lt;ulink linkID="1009841" linkType="Company"&gt;Santhera Pharmaceuticals&lt;/ulink&gt; acquired a  worldwide (excluding  Japan and Korea) sublicense option for vamorolone from Idorsia [&lt;ulink linkID="2096928" linkType="Reference"&gt;2096928&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In November 2018,  data filing with the FDA was expected by the end of 2020 [&lt;ulink linkID="2096928" linkType="Reference"&gt;2096928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017,  the  FDA granted  Fast Track designation for vamorolone for the treatment    of DMD  [&lt;ulink linkID="1961950" linkType="Reference"&gt;1961950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011,  vamorolone was designated an Orphan Drug for DMD by the FDA [&lt;ulink linkID="1256208" linkType="Reference"&gt;1256208&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In November 2018,  data filing with the EMA was expected in 2021 [&lt;ulink linkID="2096928" linkType="Reference"&gt;2096928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, the COMP of the EMA recommended granting the drug Orphan status for the treatment of DMD [&lt;ulink linkID="1579148" linkType="Reference"&gt;1579148&lt;/ulink&gt;]; in August 2014, Orphan status was granted [&lt;ulink linkID="1592372" linkType="Reference"&gt;1592372&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2016, a phase IIb trial was planned [&lt;ulink linkID="1869507" linkType="Reference"&gt;1869507&lt;/ulink&gt;]. In February 2018, a randomized, double-blind, parallel-group, placebo and active-controlled, phase IIb trial (&lt;ulink linkID="329964" linkType="Protocol"&gt;NCT03439670&lt;/ulink&gt;; VBP15-004) to evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of vamorolone administered orally at daily doses of 2 and 6 mg/kg versus prednisone 0.75 mg/kg/day and placebo over a treatment period of 24 weeks, and to evaluate persistence of effect over a treatment period of 48 weeks in ambulant boys (expected n = 120) ages 4 to &amp;lt;7 years with DMD was planned in the US and Canada. In June 2018, the trial was initiated. At that time, the trial was expected to complete in May 2020 [&lt;ulink linkID="2066755" linkType="Reference"&gt;2066755&lt;/ulink&gt;]. In August 2018, the first patient was enrolled in the trial and the study was to begin in Israel, the UK, Sweden, Australia, Netherlands, Belgium, and Czech Republic [&lt;ulink linkID="2066668" linkType="Reference"&gt;2066668&lt;/ulink&gt;]. In November 2018, the trial (VISION-DMD) was ongoing [&lt;ulink linkID="2096928" linkType="Reference"&gt;2096928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, an open-label, 24-month, multicenter, non-randomized, long-term extension phase  II trial (&lt;ulink linkID="287053" linkType="Protocol"&gt;NCT03038399&lt;/ulink&gt;: VBP15-LTE) was initiated  in  the US in pediatric patients (expected n = 48) with   DMD  to evaluate the long‑term safety and efficacy of vamorolone. The trial would recruit patients who participated in VBP15-002 or VBP15-003. At that time, the trial was to begin in Australia, Israel, Sweden  and in the UK and was expected to complete in January 2021 [&lt;ulink linkID="1899026" linkType="Reference"&gt;1899026&lt;/ulink&gt;]. In October 2018, 46 out of 48 patients completed the extension study and remained enrolled in the two-year long-term extension study [&lt;ulink linkID="2079593" linkType="Reference"&gt;2079593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In April 2016, an  open-label, non-randomized, parallel-assigned, multicenter, extension phase II trial (&lt;ulink linkID="260111" linkType="Protocol"&gt;NCT02760277&lt;/ulink&gt;; VBP15-003; 1R44NS095423-01; 1U34AR068616-01) to assess the long-term safety and efficacy of vamorolone in boys (expected n = 30) with DMD was to begin in August 2016. The study was to complete in August 2017 [&lt;ulink linkID="1763826" linkType="Reference"&gt;1763826&lt;/ulink&gt;]. In August 2016, patient enrollment (expected n = 48) was initiated in the multiple ascending dose, cohort phase IIa extension trial (part of VISION-DMD project) in the US, Canada, Australia, Israel, Sweden and the UK  [&lt;ulink linkID="1798762" linkType="Reference"&gt;1798762&lt;/ulink&gt;], [&lt;ulink linkID="1763826" linkType="Reference"&gt;1763826&lt;/ulink&gt;]. In June 2018, early top line data from the trial from 4-7 years old boys with DMD were reported. Dose-related improvements of multiple function tests of strength and endurance were observed. Clinical efficacy was demonstrated at the 2 mg/kg/day and the 6 mg/kg/day vamorolone doses compared to data from untreated patients. Vamorolone exhibited limited metabolic disturbance and bone turnover change at  2  and   6 mg/kg/day doses   [&lt;ulink linkID="2049548" linkType="Reference"&gt;2049548&lt;/ulink&gt;]. In October 2018, all 48 patients were continued into the 24-week extension study [&lt;ulink linkID="2079593" linkType="Reference"&gt;2079593&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2016, an open-label, non-randomized, parallel-assigned, phase II trial (&lt;ulink linkID="260105" linkType="Protocol"&gt;NCT02760264&lt;/ulink&gt;; VBP15-002; 1R44NS095423-01; 1U34AR068616-01) to evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of vamorolone in patients (expected n = 30) with DMD was planned for June 2016. At that time, the trial was expected to complete in August 2017. In June 2016, the study was initiated in the US, Australia, Canada, Israel, Sweden and the UK  [&lt;ulink linkID="1760091" linkType="Reference"&gt;1760091&lt;/ulink&gt;]. In September 2018, clinical data were published. In the multiple-dose ascending trial, over 48 boys (4 to &amp;lt; 7 years) with DMD were enrolled to assess the pharmacodynamic biomarkers in three context; secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover), exploratory outcomes for drug mechanism of action and for expanded pharmacodynamic safety. Data demonstrated that the drug showed improved safety versus glucocorticoids, reduction in adrenal suppression, dose-responsive decrease in serum creatine kinase activity, decreased steroid-associated safety concerns and was well-tolerated. Further, the drug had less potential for side effects compared to &lt;ulink linkID="6016" linkType="Drug"&gt;deflazacort&lt;/ulink&gt; and prednisone [&lt;ulink linkID="2079723" linkType="Reference"&gt;2079723&lt;/ulink&gt;]; in October 2018, similar data were reported [&lt;ulink linkID="2079593" linkType="Reference"&gt;2079593&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2016, a phase IIb registration trial was planned from the six month extension phase IIa trial [&lt;ulink linkID="1762487" linkType="Reference"&gt;1762487&lt;/ulink&gt;].  In September 2016,  phase IIb trial were expected to begin in the second half of 2017 [&lt;ulink linkID="1798762" linkType="Reference"&gt;1798762&lt;/ulink&gt;]. In September 2017, enrollment in blinded, placebo- and glucocorticoid-controlled phase IIb trials was expected to begin later in 2017  [&lt;ulink linkID="1961950" linkType="Reference"&gt;1961950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, the company expected to initiate phase IIa trial in DMD patients following the completion of phase I trial [&lt;ulink linkID="1603478" linkType="Reference"&gt;1603478&lt;/ulink&gt;]; in February 2015, long-term clinical trials were expected to be initiated later in 2015 following the completion of chronic toxicology studies    [&lt;ulink linkID="1636585" linkType="Reference"&gt;1636585&lt;/ulink&gt;]. In September 2016, the phase IIa trials were still planned to assess multiple ascending doses of vamorolone in 4-7 year old boys with DMD [&lt;ulink linkID="1798763" linkType="Reference"&gt;1798763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, phase I studies for DMD were expected to be initiated in that year followed by a phase IIa trial in DMD patients [&lt;ulink linkID="1603478" linkType="Reference"&gt;1603478&lt;/ulink&gt;]. In February 2015, a phase I trial was initiated in healthy adult volunteers to evaluate the safety, tolerability and pharmacokinetics of vamorolone [&lt;ulink linkID="1634793" linkType="Reference"&gt;1634793&lt;/ulink&gt;]. By November 2015, phase I trials had been completed [&lt;ulink linkID="1869507" linkType="Reference"&gt;1869507&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2018,  preclinical data were reported from mouse model. The drug stabilized dysferlin-deficient muscle cell membrane and improved repair of dysferlin-deficient mouse (B6A/J) myofibers injured by focal sarcolemmal damage, eccentric contraction-induced injury or injury due to spontaneous in vivo activity, whereas prednisolone showed no such activities. Also, observed improved cellular and pre-clinical efficacy, and safety of vamorolone in B6A/J mice, compared to prednisolone [&lt;ulink linkID="2143835" linkType="Reference"&gt;2143835&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, preclinical data were presented at the 2017 ATS International Conference in Washington DC. In life-extended CF human bronchial epithelial cells (HBE) cultured at air liquid interface (ALI) cells, there were increases in the levels of NFκB inhibitory protein IκB-beta under homeostatic conditions. VBP-15 (1 microM) exposure in these cells decreased the levels of endogenously increased IκB-beta levels in CF cells under constitutive conditions [&lt;ulink linkID="1929543" linkType="Reference"&gt;1929543&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;.In September 2015, a preclinical trial in a pig model of cystic fibrosis was underway [&lt;ulink linkID="1691990" linkType="Reference"&gt;1691990&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2015, preclinical data from experimental autoimmune encephalomyelitis (EAE) mouse model. Data demonstrated that, vamorolone reduced both disease onset and severity of multiple sclerosis and inhibited the production of NFκB-regulated pro-inflammatory transcripts in human macrophages [&lt;ulink linkID="1692014" linkType="Reference"&gt;1692014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, chronic toxicology studies in animals were planned  [&lt;ulink linkID="1636585" linkType="Reference"&gt;1636585&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, further preclinical data in animal models of muscular dystropy  were reported, whereby vamorolone did not show growth stunting and immune suppression (side effects commonly seen with stereoidal anti-inflammatories) [&lt;ulink linkID="1636585" linkType="Reference"&gt;1636585&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, preclinical data in mdx mice model were reported. Data demonstrated that, vamorolone had a significant improvement in muscle strength and function similar or superior to prednisone with a dose-dependent reduction in muscle inflammation. At that time, other types of muscular dystrophy studies in mouse models were ongoing  [&lt;ulink linkID="1603478" linkType="Reference"&gt;1603478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were reported. Data demonstrated that vamorolone reduced inflammatory activity in vivo in multiple models of disease including the TNBS-induced mouse model of colitis [&lt;ulink linkID="1627109" linkType="Reference"&gt;1627109&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, preclinical data were reported. Data demonstrated that vamorolone in a murine model of sickle cell anemia favorably affected the alterations in pain response [&lt;ulink linkID="1627112" linkType="Reference"&gt;1627112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, preclinical data from allergic lung inflammation mouse model were published. Data demonstrated that, vamorolone showed a similar reduction of NFκB activity, leukocyte degranulation, and pro-inflammatory cytokine release from human bronchial epithelial cells to prednisone. Also, the drug reduced inflammation of the lung in vivo to a similar extent of prednisone.   vamorolone does  not shortens the tibia in mice compared to prednisone at 5 week treatment regimen [&lt;ulink linkID="1692010" linkType="Reference"&gt;1692010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, TRND planned to conduct pre-IND meeting with the FDA in the first quarter of 2013 [&lt;ulink linkID="1365130" linkType="Reference"&gt;1365130&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2012, vamorolone have been found to improve muscle function and reduce muscle inflammation in mdx mice with a DMD-like disease [&lt;ulink linkID="1288502" linkType="Reference"&gt;1288502&lt;/ulink&gt;]. In September 2013, data were published. vamorolone inhibited the transcription factor NF-kB in animal cell types [&lt;ulink linkID="1475238" linkType="Reference"&gt;1475238&lt;/ulink&gt;], [&lt;ulink linkID="1475416" linkType="Reference"&gt;1475416&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2011, a lead compound vamorolone had been identified. Preclinical studies had demonstrated that vamorolone and dexamethasone (DEX) reduced asthmatic epithelial inflammatory cytokines TGFbeta-1, IL-10, IL-13, and IL-1 beta. The compounds also improved regeneration when compared to unexposed asthmatic cultures. DEX and vamorolone exposed cultures showed improved mitotic synchrony and wound regeneration. Vamorolone lacked receptor-mediated transcriptional activity [&lt;ulink linkID="1182200" linkType="Reference"&gt;1182200&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Vamorolone, described as a "dissociative glucocorticoid", is designed to produce fewer side effects by eliminating the genomic effects of glucocorticoids while retaining their non-genomic effects [&lt;ulink linkID="1288502" linkType="Reference"&gt;1288502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, the EMA's Pediatric Committee (PDCO) adopted a positive opinion on pediatric investigation plan (PIP) for vamorolone in the treatment of DMD [&lt;ulink linkID="1793043" linkType="Reference"&gt;1793043&lt;/ulink&gt;]. In January 2018, the PDCO adopted a positive opinion on  a further PIP for vamorolone in the treatment of DMD [&lt;ulink linkID="2004201" linkType="Reference"&gt;2004201&lt;/ulink&gt;]. In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for treatment of Duchenne muscular dystrophy [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1760091" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1899026" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1760091" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1760091" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1760091" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2013-02-01T00:00:00.000Z</StatusDate><Source id="1365130" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2019-04-22T00:00:00.000Z</StatusDate><Source id="2143834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3289">Becker muscular dystrophy</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="303">Sickle cell anemia</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2013-02-01T00:00:00.000Z</StatusDate><Source id="1365130" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3289">Becker muscular dystrophy</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2019-04-22T00:00:00.000Z</StatusDate><Source id="2143834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-08-27T00:00:00.000Z</StatusDate><Source id="2143835" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2011-03-30T00:00:00.000Z</StatusDate><Source id="1180145" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2014-10-20T00:00:00.000Z</StatusDate><Source id="1603478" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate>2019-04-22T00:00:00.000Z</StatusDate><Source id="2143834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2475">Dermatomyositis</Indication><StatusDate>2019-04-22T00:00:00.000Z</StatusDate><Source id="2143834" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3250">Limb girdle muscular dystrophy</Indication><StatusDate>2018-08-27T00:00:00.000Z</StatusDate><Source id="2143835" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2010-11-01T00:00:00.000Z</StatusDate><Source id="1182509" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2015-02-19T00:00:00.000Z</StatusDate><Source id="1634793" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2017-01-31T00:00:00.000Z</StatusDate><Source id="1899026" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2017-01-31T00:00:00.000Z</StatusDate><Source id="1899026" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2016-11-03T00:00:00.000Z</StatusDate><Source id="1869507" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1060605">ReveraGen BioPharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2014-07-08T00:00:00.000Z</StatusDate><Source id="1579148" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-03-24T00:00:00.000Z</MileStoneDate><Source id="1961950" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2015-05-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-08-22T00:00:00.000Z</MileStoneDate><Source id="1592372" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-12-02T00:00:00.000Z</MileStoneDate><Source id="1256208" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1060605">ReveraGen BioPharma Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-01-26T00:00:00.000Z</MileStoneDate><Source id="2004201" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00822"><Name>Glucocorticoid receptor</Name><SwissprotNumbers><Swissprot>O13186</Swissprot><Swissprot>O46567</Swissprot><Swissprot>O73673</Swissprot><Swissprot>P04150</Swissprot><Swissprot>P06536</Swissprot><Swissprot>P06537</Swissprot><Swissprot>P35547</Swissprot><Swissprot>P49115</Swissprot><Swissprot>P49843</Swissprot><Swissprot>P49844</Swissprot><Swissprot>P59667</Swissprot><Swissprot>P79269</Swissprot><Swissprot>P79686</Swissprot><Swissprot>Q5R9P5</Swissprot><Swissprot>Q95267</Swissprot><Swissprot>Q9N1U3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01338"><Name>Mineralocorticoid receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-01442"><Name>Nuclear factor kappa B</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009841">Santhera Pharmaceuticals AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045019">Muscular Dystrophy Association</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1052462">The Foundation to Eradicate Duchenne</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1052463">CureDuchenne</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1059771">Parent Project Muscular Dystrophy</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1059977">European Commission</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1060605">ReveraGen BioPharma Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>13</CountTotal></Company><Company><Company id="1149835">Idorsia Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="20645">Northwestern University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20658">University of Pennsylvania</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21243">The University of Newcastle Upon Tyne</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>9</CountActive><CountInactive>0</CountInactive><CountTotal>9</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C</Smiles></StructureSmiles><Deals><Deal id="137802" title="ReveraGen to receive funding from the US Government to develop non-hormonal steroids for various indications  "/><Deal id="137804" title="ReveraGen to receive funding from the MDA to develop non-hormonal steroid for Duchenne muscular dystrophy      "/><Deal id="144147" title="ReveraGen and NIH to collaborate on the development of VBP-15 to treat DMD"/><Deal id="146615" title="US Department of Defense to fund ReveraGen's study of VBP-15"/><Deal id="146616" title="Foundation to Eradicate Duchenne to fund ReveraGen's study of VBP-15 against  Duchenne muscular dystrophy"/><Deal id="146618" title="CureDuchenne Foundation to fund ReveraGen's study of VBP-15"/><Deal id="153267" title="PPMD to award ReveraGen BioPharma funding for the chronic toxicology studies of VBP-15 against Duchenne muscular dystrophy"/><Deal id="160606" title="NINDS to award ReveraGen BioPharma funding to develop VBP-15 against Duchenne dystrophy      "/><Deal id="162456" title="EU to award University of Newcastle funding to develop vamorolone against DMD "/><Deal id="211710" title="Actelion to acquire a worldwide option to in-license vamorolone from ReveraGen for DMD        "/><Deal id="241546" title="Muscular Dystrophy Association to award funding to ReveraGen BioPharma for phase I clinical trial of VBP-15 against Duchenne dystrophy"/><Deal id="244375" title="Actelion to spin-out its drug discovery operations into new Swiss company, Idorsia "/><Deal id="251405" title="Santhera to develop and commercialize Idorsia's vamorolone against DMD worldwide excluding Japan and South Korea "/><Deal id="251428" title="Idorsia to conduct research and co-develop ReveraGen's vamorolone for DMD worldwide "/><Deal id="255333" title="ReveraGen and Northwestern University to develop vamorolone for Juvenile Dermatomyositis     "/><Deal id="255335" title="ReveraGen and University of Pennsylvania to develop vamorolone for AAV     "/></Deals><PatentFamilies><PatentFamily id="2436020" number="WO-2009155056" title="Non-hormonal steroid modulators of NF-κB for treatment of disease"/><PatentFamily id="2541488" number="WO-2013082253" title="Non-hormonal steroid modulators of NF-κB for treatment of disease"/><PatentFamily id="3616723" number="WO-2017075580" title="Compositions and methods for treatment of peroxisomal disorders and leukodystrophies"/><PatentFamily id="819855" number="WO-2011127048" title="Non-hormonal steroid modulators of NF-κB for treatment of disease"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ReveraGen BioPharma Inc" id="1060605"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PharMac LLC" id="1065567"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Children's National Medical Center" id="21053"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kennedy Krieger Institute" id="25533"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>